Tesaro (niraparib)

Tesaro (niraparib) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Tesaro (niraparib) General Information

Description

Commercialization and clinical development rights of niraparib. The asset is the rights of development of niraparib, a novel poly ADP-ribose polymerase (PARP), inhibitor, used for the treatment of all tumor types excluding prostate cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Japan
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Tesaro (niraparib) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tesaro (niraparib)‘s full profile, request access.

Request a free trial

Tesaro (niraparib) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Tesaro (niraparib)‘s full profile, request access.

Request a free trial